Shimedicine European-Italian first imitation of Afatini listing application accepted

Pharmaceutical Network May 28th, May 27th, CDE official website shows that the stone medicine Oyi according to imitation 4 categories of malayacid afatinib tablets submitted to the listing application to be accepted by the contractorMalay acid actatinib for the treatment of EGFR mutation-positive non-small cell lung cancer patients, the current domestic market no generic drugs on the marketthe listing application of Malaya afatinib tablets
Malay acid afatinib tablet original research manufacturer for Bollinger Ingham, approved in the United States in 2013 for the treatment of EGFR mutation-positive non-small cell lung cancer patients, is the world's first irreversible EGFR lung cancer targeted drugIn February 2017, Malaya Afatinib was approved for listing in China, the first second-generation EGFR-TKI to be listed in Chinameters net data show that in 2019, China's urban public, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public health institutions) terminal Malaya Afatini tablets sales of 260 million yuan, an increase of 2148.36 percent year-on-yearchina's public medical institutions terminal Afatini sales (unit: million yuan)the current domestic market no Afatini generic drugs approved for listingHowson, Qilu, Zhengdayan, Collum, Yangzijiang, Yamsan Pharmaceuticals and other 6 pharmaceutical companies in accordance with the imitation of 4 categories submitted by the Malay acid afatinib tablets listed applications in the reviewAfatini listing application in thesource: CDE, Minet databasereview data statistics as of May 27, 2020, if there is a mistake, please point in the positive.